vatalanib has been researched along with B-Cell Chronic Lymphocytic Leukemia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Erdfelder, F; Filipovich, A; Gandhirajan, RK; Gehrke, I; Hallek, M; Hertweck, M; Kreuzer, KA; Paesler, J; Poll-Wolbeck, SJ; Uhrmacher, S | 1 |
1 other study(ies) available for vatalanib and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Indazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Phosphorylation; Phthalazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Xenograft Model Antitumor Assays | 2010 |